OSE Immunotherapeutics SA (EPA:OSE)
5.71
+0.38 (7.13%)
Nov 10, 2025, 5:35 PM CET
OSE Immunotherapeutics Revenue
In the year 2024, OSE Immunotherapeutics had annual revenue of 83.44M EUR with 3,646.52% growth. OSE Immunotherapeutics had revenue of 862.00K in the half year ending December 31, 2024, a decrease of -61.77%.
Revenue
83.44M
Revenue Growth
+3,646.52%
P/S Ratio
1.43
Revenue / Employee
1.30M
Employees
64
Market Cap
119.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 83.44M | 81.21M | 3,646.52% |
| Dec 31, 2023 | 2.23M | -16.08M | -87.83% |
| Dec 31, 2022 | 18.30M | -8.00M | -30.43% |
| Dec 31, 2021 | 26.31M | 15.89M | 152.48% |
| Dec 31, 2020 | 10.42M | -15.53M | -59.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
| Sartorius Stedim Biotech | 2.95B |
OSE Immunotherapeutics News
- 5 weeks ago - OSE Immunotherapeutics (ORPOF) Appoints Interim CEO Marc Le Bozec - GuruFocus
- 5 weeks ago - OSE Immunotherapeutics replaces CEO Nicolas Poirier, appoints Marc Le Bozec as interim CEO - Seeking Alpha
- 7 weeks ago - OSE Immunotherapeutics SA (ORPOF) Shareholder/Analyst Call Transcript - Seeking Alpha